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Objectives: Use of oral contraceptive pills (OCP) increases the risk of cerebral venous sinus
thrombosis (CVST). Whether this risk varies by type, duration, and other forms of hormonal
contraceptives is largely unknown. This systematic review and meta-analysis update the
current state of knowledge.
Methods: We performed a search to identify all published studies on the association
between hormonal contraceptive use and risk of CVST in women aged 15–50 years.
Results: Of 861 studies reviewed, 11 were included.The pooled odds of developing CVST
in women aged 15–50 years taking OCPs was 7.59 times higher compared to women not
taking OCPs (OR=7.59, 95% CI 3.82–15.09). Data are insufficient to make conclusions
about duration of use and other forms of hormonal contraceptives.
Conclusion: Oral contraceptive pills use increases the risk of developing CVST in women of
reproductive age. Future studies are required to determine if duration and type of hormonal
contraceptives modify this risk.
Keywords: hormonal contraceptives, birth control pill, oral contraceptive pill, cerebral venous sinus thrombosis,
cerebral venous thrombosis
BACKGROUND
Cerebral venous sinus thrombosis (CVST) is a form of stroke
whereby thrombosis occurs in the cerebral venous sinuses or veins.
The incidence of CVST has been estimated at three to five cases
per million population per year (1, 2). This represents about 0.5–
1% of all strokes (1, 2). CVST affects the younger population (age
<50 years) and is three times more common in women than men
(1). Significant disability leading to dependency has been reported
in about 5–10% of patients, and mortality rates range from 3 to
15% (3).
Several risk factors have been identified for CVST. These include
medical conditions that increase the likelihood of thrombus for-
mation such as thrombophilias, neoplasms, inflammatory condi-
tions, transient situations (such as pregnancy, post-partum period,
surgery, trauma, dehydration, CNS infections), and medications
[such as oral contraceptive pills (OCP)] (1, 2, 4). Use of OCP
has been shown in multiple observational studies to increase the
odds of CVST by 5- to 22-fold (5). The presence of an inher-
ited thrombophilia (such as Factor V Leiden or prothrombin-gene
mutation) increases the odds further. Nonetheless, many of the
previous studies were underpowered or had varying inclusion and
exclusion criteria and did not adjust for the presence of other
risk factors when evaluating the association between OCP use and
CVST. Although a prior systematic review and meta-analysis were
performed on this association, it was conducted over 7 years ago
and did not make a distinction between those with thrombophilia
and those without thrombophilia in the assessment of OCP use
and risk of CVST (5). In addition, this review did neither evaluate
information on type of OCP used and risk of CVST nor risk of
CVST with the use of other hormonal contraceptives.
The objective of this systematic review and meta-analysis is to
update available knowledge in regards to the association of CVST
and OCP use among women aged 15–50 years. In addition, we
reviewed the literature to determine if there was data on specific
types of OCPs, duration of use, and other forms of hormonal con-
traceptives, such as transdermal patches, Depo-Provera injections,
and intra-uterine devices, and the risk of developing CVST. Where
possible, we tried to account for potential modifying and con-
founding variables when reporting on these associations and we
used meta-regression techniques to explore heterogeneity among
studies.
METHODS
SEARCH STRATEGY
We performed a systematic review and meta-analysis following a
predetermined protocol in accordance with the Meta-analysis of
Observational Studies in Epidemiology (MOOSE) (6). We identi-
fied all potentially relevant articles using MEDLINE (from 1966 to
June 2014), EMBASE (from 1980 to June 2014), Cochrane system-
atic review, the Cochrane Center for Clinical Trials, and CINAHL.
All searches were carried out without any language restrictions,
using free text and medical subject headings. We performed our
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search using two themes. The first theme included terms related
to the exposure: hormonal contraceptives or oral contraceptives
or OCP or birth control pill or ethinyl estradiol or desogestrel or
levonorgestrel or Depo-Provera or Mirena IUD or Nuva-Ring or
hormonal patch or Evra. The second theme included terms related
to the outcome: cerebral-vein thrombosis or CVST or intracra-
nial venous thrombosis or intracranial vein thrombosis or sinus
thrombosis or dural thrombosis or dural venous thrombosis or
dural vein thrombosis or venous infarct. Finally, we combined
the terms from Theme 1 and Theme 2 with the Boolean oper-
ator AND. These terms were identified from exemplar articles
identified in a scout search. Where appropriate, “permuted index”
or “Tree/Thesaurus” was used to identify related terms including
drug or generic names for hormonal contraceptives that could be
included in the search. A theme was not used for study design in
our initial search.
To identify articles that were yet to be cited or yet to be
indexed in the electronic databases mentioned above, we hand-
searched major neurology and internal medicine journals pub-
lished after December 2011 and the reference lists of all identi-
fied relevant publications. We also searched abstracts of major
national and international Neurology, Internal Medicine, and
Neurosurgery conferences from January 2009 until June 2014
using Conference Papers Index. In addition, we contacted local
experts in stroke for information about other potential ongoing
or unpublished studies. We also searched gray literature includ-
ing unpublished theses and ongoing studies using the University
of Calgary’s database at http://libguides.ucalgary.ca/greylit and
the website http://clinicaltrials.gov/for unpublished clinical tri-
als. Abstracts or papers in languages other than English were
translated.
STUDY SELECTION
Inclusion and exclusion criteria
Articles were independently evaluated for eligibility using a two-
stage procedure. Both primary authors (Farnaz Amoozegar, Bijoy
K. Menon) initially reviewed all citations for original articles
related to the primary study question in a broad sense. Inter-
rater agreement was measured using the kappa statistic. Disagree-
ments were resolved by consensus. Potentially relevant articles
then underwent full text review. We included studies that met
our explicit population, exposure, outcome, and design crite-
ria. The study population was limited to women of reproductive
age, specifically 15–50 years of age. Studies were excluded if the
study population included: (1) pregnant women or post-partum
women (up to 3 months after childbirth), (2) surgical patients,
(3) patients hospitalized due to trauma, and (4) patients with
prolonged immobilization. The exposure was any form of hor-
monal contraception, such as oral contraceptives pills, patches
(Evra), or injections (depo-provera). The outcome was CVST,
objectively confirmed by imaging: computed tomography (CT),
magnetic resonance imaging (MRI), or angiography/venography.
As CVST is a rare outcome, case–control studies were the most
commonly employed study design to measure this association.
However, cohort studies have also been performed in this area.
Given that randomized controlled trials are not feasible, we limited
our review to case–control and cohort designs.
Data extraction and study quality assessment
The same reviewers (Farnaz Amoozegar, Bijoy K. Menon) inde-
pendently extracted data from all included studies. Disagreements
were resolved by consensus. If missing data were identified for a
given study, attempts were made to contact the authors to obtain
the data. When multiple papers published the same data, we used
the latest publication, and supplemented it, if necessary, with data
from earlier publications.
Study quality was assessed based on the following crite-
ria/questions:
(1) Were cases and controls well defined as per primary study
hypothesis? Well-defined cases had objective confirmation of
CVST and were 15–50 years of age, without autoimmune,
neoplastic, or infectious diseases and not post-traumatic,
pregnant, post-partum, or post-menopausal. Objective con-
firmation of CVST involved demonstration of thrombosis
on one or more appropriate imaging modalities, such as CT
venography, MR venography, or angiography. Well-defined
controls were healthy individuals, between 18 and 50 years,
and unrelated biologically to the patient.
(2) Were controls matched to cases? We defined this as being
matched for at least one of: age, body mass index (BMI),
smoking status, educational status, or ethnicity.
(3) Was there clear documentation of recent exposure to hor-
monal contraceptive use? This was defined as exposure to
hormonal contraceptives within 2 weeks of CVST diagnosis
for cases, or time of assessment for controls. Case–control
studies reporting on exposure to hormonal contraceptives in
the remote past may over-report exposure as an inherent recall
bias (7); hence the reason we chose this as a criteria to assess
study quality.
(4) Were potential confounders/modifiers addressed? Age, BMI,
smoking status, hyper-homocysteinemia, Prothrombin-gene
mutation, and Factor V Leiden) were the factors we looked
for to address confounding and effect modification.
(5) Werepost hoc statistical adjustments for confounders/modifiers
performed before reporting on the exposure-disease
relationship?
STATISTICAL METHODOLOGY
The odds ratio (OR) was used as the common measure of asso-
ciation across studies. When studies only reported on stratum-
specific OR for the relationship between the use of hormonal
contraceptives and occurrence of CVST stratified by potential con-
founding variables, we calculated the assumed common OR across
all stratifying variables using the Mantel–Haenszel method. Since
the relationship between the use of hormonal contraceptives and
occurrence of CVST may not have one true population estimate,
primarily due to residual confounding by unknown genetic and
environmental variables, we chose to derive pooled estimates using
the Der-Simonian and Laird “random effects model.” To visu-
ally assess the OR estimates and corresponding 95% confidence
intervals across studies, we also generated a forest plot.
A higher prevalence of hormonal contraceptive use in the popu-
lation could potentially result in over-reporting of use. In addition,
a higher prevalence of poverty, anemia, poor nutritional status,
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dehydration, and other residual confounding factors in develop-
ing countries may increase the incidence of CVST, when com-
pared to developed countries. We therefore stratified all included
studies by prevalence of hormonal contraceptive use and by devel-
oped/developing countries. We explored statistical heterogeneity
by stratifying studies using “study quality” variables, prevalence
of hormonal contraceptive use (> or ≤ median prevalence of
OCP use in the control arm of all studies) and whether conducted
in developing vs. developed countries. Statistical heterogeneity for
the pooled OR was evaluated using the I 2 statistic and the Cochran
Q statistic.
In order to assess the nature of cumulative evidence over
time on our research question, we performed a cumulative meta-
analysis using the Der-Simonian and Laird random effects model.
Finally, we tested for publication bias using Begg’s rank correla-
tion test for small study effects (continuity corrected) and standard
funnel plots. All p-values are two-sided, with p< 0.05 considered
statistically significant. Analyses were performed using Stata/SE
12.1 software (StataCorp LP, College Station, TX, USA).
RESULTS
STUDY IDENTIFICATION AND SELECTION
After excluding 148 duplicates, we identified 857 studies using our
search strategy from MEDLINE (n= 249), EMBASE (n= 754),
Cochrane systematic review (n= 2), and the Cochrane Center
for Clinical Trials (n= 0) (Figure 1). An additional four studies
were identified by handsearching the literature. The two reviewers
agreed 94.4% of the time at this stage (unweighted kappa= 0.53).
We excluded 811 articles after initial screening of titles and
abstracts. Of the 50 studies selected for full text review, 11 studies
were included in the systematic review (8–18). Of these 11 studies,
only two studies reported on an association between the use of
third generation OCPs and risk of CVST (12, 18). Nonetheless,
data reported in these studies were such that we could not estimate
FIGURE 1 | Flow diagram for studies included in systematic review and
meta-analysis.
an OR for CVST in women taking OCPs vs. those not taking them,
i.e., relevant data were not available for a meta-analysis despite
contacting the authors. Thus only 9 of 11 studies contained suffi-
cient information for a meta-analysis to calculate the pooled odds
of CVST. These nine studies were in the English language. Study
period ranged from 1996 to 2005. All were case–control studies.
Two studies were multi-center and three were from developing
countries. Total subjects enrolled in the studies ranged from 32 to
2288. All studies reported only on the use of oral contraceptives.
Only two studies reported on the duration of exposure to oral
contraceptives. Characteristics of these nine studies are described
in detail in Table 1.
STUDY QUALITY
Of the nine studies included, the quality ranged from moderate
to high (Table 2). Four studies had well-defined cases, and five
studies had well-defined controls. Controls were matched to case
characteristics in five studies. Exposure to hormonal contracep-
tives within 2 weeks prior to CVST in cases and study assessment in
controls was recorded in only three studies. Potential confounders
and modifiers were discussed in five studies to varying extents.
Variable adjustment for these factors occurred in the same five
studies.
EFFECT OF HORMONAL CONTRACEPTIVE USE ON OCCURRENCE OF
CVST
All 11 studies included in the systematic review show an association
between the use of OCPs and CVST; use of OCPs increases the odds
of developing CVST. Among the nine studies that reported OR, the
pooled odds of developing CVST in women of reproductive age
taking oral contraceptives was 7.59 times the odds of developing
CVST for those not taking oral contraceptives (OR= 7.59, 95% CI
3.82–15.09, random effects model, Figure 2). The two studies that
reported on the use of third generation OCPs suggested that the use
of these newer generation OCPs was associated with an increased
risk of CVST when compared to previous generation OCPs (12,
18). De Bruijn et al. assessed the risk of CVST with third generation
OCPs and found an OR of 2 for risk of CVST with third-generation
OCPs as compared to other OCPs (12). The actual number of
healthy controls taking OCPs and third-generation OCPs were
not available to us, despite contacting study authors. As a result,
we were unable to calculate an OR for CVST with third-generation
OCP use. Jick et al. used a cohort study design for assessing the
incidence of CVST in users of four types of hormonal contracep-
tives (18). The incidence rate ratio (IRR) for CVST per 100,000
woman-years was 2.7 [95% confidence interval (95% CI)= 0.9–
6.3], 1.6 (95% CI= 0.7–3.3), 0.7 (95% CI= 0.1–2.4), and 0.0 (95%
CI= 0.0–4.8), respectively, in users of desogestrel, norgestimate,
levonorgestrel, and the contraceptive patch. The incidence rate
(IR) for non-exposed women was 0.4 per 100,000 woman-years
(95% CI= 0.1–1.3). The authors, when contacted, had person
time data for exposure and non-exposure; however, the study
design was such that we could not calculate our summary esti-
mate, i.e., the OR. In addition, original clinical records to confirm
the diagnosis of CVST could not be obtained in this study.
Heterogeneity between the nine studies included in the meta-
analysis was high (I 2= 72.1%, p< 0.001 for the Cochran Q
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Table 1 | Characteristics of studies included (n=9).
Study (Author, year) Study
Setting
Cases
(number)
Age range
in years
reported
for cases
Cases (description) Controls
(number)
Age range
in years
reported
for controls
Controls
(description)
Type of
hormonal
contraception
Duration of
exposure to
hormonal
contraceptives
Variables
matched for
a priori
Martinelli et al., 1996 (8) Single
center,
Italy
16 21–64 First episode of CVT
referred to the local
thrombosis center;
patients with neoplastic,
autoimmune or infectious
disease, pregnant and
post-partum women
were excluded.
48 not
reported
Healthy controls with
no history of
thrombosis; no
pregnant, post-partum
women were included
Oral
contraceptive
only
Not reported Age matched
Martinelli et al., 1998 (9) Single
center,
Italy
25 15–64 (not
reported after
excluding
pregnant,
post-partum
and post-
menopausal
women)
First episode of CVT
referred to the local
thrombosis center; none
of them had neoplastic,
autoimmune, or
infectious disease;
post-traumatic patients,
pregnant and
post-partum women as
well as post-menopausal
women were excluded
88 18–64 Healthy, biologically
unrelated friends or
partners of patients
with no history of
thrombosis; pregnant
and post-partum
women as well as
post-menopausal
women were also
excluded
Oral
contraceptives
only
Cases
(median=15
months);
controls
(median=26
months)
Age,
geographic
location and
level of
education
Reuner et al., 1998 (10) Multi
center,
Ger-
many
31 17–69 Patients with CVT aged
17–50 years; no data on
whether patients with
neoplastic, autoimmune,
infectious disease were
excluded; patients’
post-partum and in
puerperium were
excluded
148 18–63 Healthy blood donors
aged 18–50 years
Oral
contraceptive
Not reported Age matched
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Table 1 | Continued
Study (Author, year) Study
Setting
Cases
(number)
Age range
in years
reported
for cases
Cases (description) Controls
(number)
Age range
in years
reported
for controls
Controls
(description)
Type of
hormonal
contraception
Duration of
exposure to
hormonal
contraceptives
Variables
matched for
a priori
de Bruijn et al., 1998 (11) Multi-
centre,
Nether-
lands
40 18–54 Patients with CVT who
participated in a
treatment trial with
heparin; younger than 18,
pregnant and puerperium
women were excluded
2248 18–49 Women aged
18–49 years from the
continuous health
interview survey of the
Central Department of
Statistic, Netherlands
(pregnant women were
not excluded)
Oral
contraceptives
only
Not reported No
Martinelli et al., 2003 (13) Single
center,
Italy
80 12–64
(includes male
patients)
First episode of CVT
referred to the local
thrombosis center;
patients with neoplastic,
autoimmune, or
infectious disease,
post-traumatic patients,
pregnant and
post-partum women as
well as post-menopausal
women were not
explicitly excluded
148 13–62
(includes
males)
Healthy, biologically
unrelated friends, or
partners of patients
with no history of
thrombosis; no
pregnant, post-partum
women, or
post-menopausal
women were included
Oral contra-
ceptives; other
hormonal
contraceptives
mentioned
Not reported Age matched
Cantu et al., 2004 (14) Single
center,
Mexico
37 14–55
(includes male
patients)
Patients with CVT
admitted to hospital; no
data on whether patients
with neoplastic,
autoimmune, infectious
disease, patients’
post-partum, or in
puerperium were
excluded
66 16–53
(includes
males)
Healthy controls of
friends or relatives of
other patients with
neurological diseases
who have no history of
vitamin intake and no
history of thrombosis
Oral
contraceptive
Not reported Recruitment
directed
toward young
women
(Continued)
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Table 1 | Continued
Study (Author, year) Study
Setting
Cases
(number)
Age range
in years
reported
for cases
Cases (description) Controls
(number)
Age range
in years
reported
for controls
Controls
(description)
Type of
hormonal
contraception
Duration of
exposure to
hormonal
contraceptives
Variables
matched for
a priori
Rodrigues et al., 2004 (15) Single
center,
Brazil
20 28 (median) Consecutive patients
with CVT; no data on
whether patients with
neoplastic, autoimmune,
infectious disease were
excluded; patients who
were post-partum were
however excluded
40 34 (median) Women aged
20–50 years that came
as outpatients for
reasons other than
thrombosis
Oral
contraceptive
only
Not reported No
Ventura et al., 2004 (16) Single
center,
Italy
14 19–44 Patients with CVT
admitted to hospital;
patients with neoplastic,
autoimmune or infectious
disease were excluded;
no data on pregnancy,
post-partum, or
puerperium. Patients
with use of OCPs
<3 months prior to CVT
were excluded
18 18–51
(including
males)
Healthy volunteers with
no history of
thrombosis, cancer,
cardiac, renal, liver, or
hematological disorders
and not taking any
drugs or OCPs for at
least 3 months prior to
recruitment
Oral
contraceptives
only
Not reported No
Gadelha et al., 2005 (17) Single
center,
Brazil
19 3–46 (not
reported for
females)
Patients with CVT
referred to the
hemostasis lab of a
tertiary university
hospital, age >15 years
and <50 years, pregnant
and post-partum women
excluded, major systemic
diseases like cancer,
diabetes, infectious or
collagen disease,
antiphospholipid
syndrome; pregnant
women or women in
puerperium excluded.
134 15–62
(includes
males)
Healthy controls
accompanying patients
to the same lab with no
history of thrombosis or
genetic relationship,
age, and race matched
Oral
contraceptives
only
Not reported Age Matched
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Table 2 | Study quality assessment. (n=9).
Study (Author, year) Well-defined
casesa
Well-defined
controlsa
Matched
controlsb
Timing of
exposurec
Adjustment for confounding
variablesd
Martinelli et al., 1996 (8) Yes Yes Yes Yes Age
Martinelli et al., 1998 (9) Yes Yes Yes Yes PT, FV
Reuner et al., 1998 (10) No No Yes No None
de Bruijn et al., 1998 (11) Yes No No No Age
Martinelli et al., 2003 (13) No Yes Yes Yes Age, BMI, smoking, HyperHcy
Cantu et al., 2004 (14) No Yes No No None
Rodrigues et al., 2004 (15) No No No No None
Ventura et al., 2004 (16) No No No No None
Gadelha et al., 2005 (17) Yes Yes Yes No PT, FV
A study is defined as being of high quality if it satisfies at least four of the five criteria above.
aWell-defined cases are objective confirmation of CVST in patients 15–50 years, without autoimmune, neoplastic, or infectious diseases and not post-traumatic,
pregnant, post-partum, or post-menopausal). Well-defined controls are healthy individuals, between age 18 and 50 years, unrelated biologically to patient); Yes fulfills
criteria for both or one of the above; “No” fulfills neither of the above criteria.
bWell-matched controls matched for at least one of age, BMI, smoking status, educational status, and ethnicity.
cExposure within 2 weeks of CVST for cases or time of assessment for controls.
dAdjustment for confounding factors is defined as (1) Controls matched for at least one of age, body mass index (BMI), smoking status, educational status, and
ethnicity and (2) adjustment during statistical analysis for age, BMI, smoking status, hyper-homocysteinemia, Prothrombin-gene mutation (PT) and factor V Leiden
(FV).
HyperHcy is hyper-homocysteinemia.
NOTE: Weights are from random effects analysis
Overall  (I-squared = 72.1%, p = 0.000)
Cantu et al (2004)
de Bruijn et al (1998)
Martinelli et al (1998)
Martinelli et al (1996)
Martinelli et al (2003)
ID
Ventura et al (2004)
Reuner et al (1998)
Study
Rodrigues et al (2004)
Gadelha et al (2005)
7.59 (3.82, 15.06)
0.88 (0.15, 5.08)
13.00 (5.00, 37.00)
26.80 (12.04, 59.68)
4.20 (1.20, 14.90)
9.56 (5.30, 17.24)
ES (95% CI)
0.43 (0.07, 2.67)
14.40 (5.80, 35.80)
21.00 (5.29, 83.41)
7.41 (1.85, 29.41)
100.00
7.95
12.33
13.62
10.69
14.89
Weight
7.67
12.92
%
9.98
9.95
1.012 83.4
Odds Ratio
FIGURE 2 | Forest plot with pooled odds ratio for relationship between oral contraceptive use and cerebral venous sinus thrombosis (random effects
model).
statistic). Cumulative meta-analysis of these studies from 1996
to 2005 shows accumulating evidence over time of a positive
association between the use of oral contraceptives and CVST
(Figure 3). To explore reasons of heterogeneity between studies, we
reported pooled ORs stratified by variables that were either “study
quality” indicators or “potential confounders” (Table 3). Studies
conducted in developed countries and those where the exposure
was measured within 2 weeks of CVST showed higher odds of the
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Martinelli et al (1996)
Martinelli et al (1998)
Reuner et al (1998)
de Bruijn et al (1998)
Martinelli et al (2003)
Cantu et al (2004)
Rodrigues et al (2004)
Ventura et al (2004)
Gadelha et al (2005)
ID
Study
4.20 (1.19, 14.80)
11.34 (1.85, 69.39)
13.00 (4.94, 34.23)
13.42 (6.73, 26.76)
12.35 (7.31, 20.87)
9.36 (4.69, 18.68)
10.35 (5.54, 19.35)
7.49 (3.52, 15.92)
7.59 (3.82, 15.06)
ES (95% CI)
1.0144 69.4
Log Odds Ratio
FIGURE 3 | Cumulative meta-analysis using the random effects model.
outcome. Despite these findings, the confidence intervals around
the estimates were wide. Furthermore, meta-regression did not
identify any of the other variables as contributing to heterogeneity
(Table 3).
ASSESSMENT OF PUBLICATION BIAS
A funnel plot of the log OR against the standard error of the log
OR shows some asymmetry, with no studies in the lower right por-
tion of the funnel and two small studies in the lower left portion
outside the pseudo 95% confidence intervals (Figure 4). Despite
a marginally significant Begg’s test (p= 0.048), it is unlikely that
this plot suggests the presence of publication bias given the small
number of studies included in the analysis and the type of studies
that are absent in the funnel plot (small studies reporting a positive
association between OCPs and CVST).
DISCUSSION
In this systematic review and meta-analysis, we found that the
odds of CVST in women of reproductive age exposed to oral con-
traceptives was about sevenfold higher than the odds of CVST in
those not taking oral contraceptives. This estimate is compara-
ble to a previous meta-analysis 7 years ago (5). In addition, our
review showed that there was insufficient evidence on the rela-
tive safety of third generation OCPs when compared to previous
generation OCPs in increasing the odds of CVST. No data were
found on the duration of exposure to OCPs and odds of CVST.
In addition, the odds of CVST with OCP use is not significantly
different in developing countries when compared to developed
countries. Our review also showed that the odds of CVST with the
use of “other hormonal contraceptives” is largely unknown. These
latter issues were not assessed in detail in the prior systematic
review.
We found moderate to high heterogeneity between studies
included in our meta-analysis. Given varying quality of studies
included in our meta-analysis, study quality itself could be respon-
sible for this heterogeneity. We did not, however, find any statistical
evidence that study quality was responsible for this heterogeneity.
Variables such as age, smoking, and prothrombotic genetic muta-
tions can certainly contribute to the risk of CVST and influence the
results obtained (3, 5). Meta-regression, however, did not identify
these variables as contributing to study heterogeneity either.
The prevalence of CVST is reported to be high in developing
countries when compared to developed countries (4, 19). How-
ever, we did not find a statistically significant increase in the odds
of CVST with OCP exposure in the developing countries. Our
results lead us to speculate that the independent biological effects
of OCPs on thrombosis may be stronger than “effect modifica-
tion” of the relationship between OCP use and risk of CVST by
factors such as malnutrition, dehydration, or anemia. A caveat to
this conclusion would be that none of our included studies were
from Sub-Saharan Africa or South Asia, regions of the world where
malnutrition and anemia are more prevalent (20, 21). This could
be because of publication bias or because no studies of sufficient
quality have yet been published from these regions. We did find
minor statistical evidence for publication bias in our study. Begg’s
test does not tell us as to the direction of this bias. Interestingly, the
funnel plot (Figure 4) shows absence of small studies reporting on
a positive association between use of OCPs and CVST. We cannot
comment if such studies from the above-mentioned regions failed
to cross the publication threshold, but that seems less likely. We do
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Table 3 | Stratified analysis of pooled odds ratios with 95% confidence
intervals (p-values generated from meta-regression).
Odds ratio 95% CI p-Value
(meta-regression)
Well-defined cases and controlsa
Yes (n=3) 8.26 3.95–17.25 0.84
No (n=6) 5.73 0.79–41.49
Timing of exposureb
Within 2 weeks (n=3) 11.15 4.44–27.98 0.51
Beyond 2 weeks (n=6) 5.58 1.91–16.31
Prevalence of exposurec
>27.7% (n=5) 6.4 1.99–20.57 0.82
≤27.7% (n=4) 8.63 3.45–21.57
Countries
Developed (n=6) 8.48 3.88–18.51 0.76
Developing (n=3) 5.57 1.01–30.61
Adjustment for confounding factorsd
Well done (n=3) 13.15 6.06–28.52 0.35
Incomplete (n=6) 5.05 1.72–14.87
aWell-defined cases are objective confirmation of CVST in patients 15–50 years,
without autoimmune, neoplastic, or infectious disease and not post-traumatic,
pregnant, post-partum, or post-menopausal). Well-defined controls are healthy
individuals, between age 18 and 50 years, unrelated biologically to patient); Yes
fulfills criteria for both or one of the above; “No” fulfills neither of the above
criteria.
bExposure within 2 weeks of CVST for cases or time of assessment for controls.
cMedian prevalence of oral contraceptive use in the control arm of all studies.
dAdjustment for confounding factors is defined as (1) Controls matched for at
least one of: age, body mass index (BMI), smoking status, educational status,
and ethnicity and (2) adjustment during statistical analysis for at least two of:
age, BMI, smoking status, hyper-homocysteinemia, prothrombin-gene mutation,
or Factor V Leiden.
feel that there is a need for high quality studies from these regions
of the world.
We only found two studies reporting on the risk of CVST with
the use of third generation OCPs (12, 18). Third-generation oral
contraceptives are combined pills containing either gestodene or
desogestrel that were developed to reduce risk of cardiovascular
disease due to their reduced androgenic activity (12). There is
controversy as to whether third generation OCPs are associated
with increased risk of venous thrombosis when compared to sec-
ond generation OCPs (22, 23). Biological basis of the increased
risk could be a differential effect on various coagulation factors,
resulting in overall increased thrombogenicity (24, 25). Propo-
nents for the use of third generation OCPs point out various biases
including a healthy user bias, recent introduction bias, prescrib-
ing bias, and referral bias, resulting in increased reported risk with
these OCPs when compared to previous generation OCPs (26, 27).
Other studies, including a detailed meta-analysis refuting these
biases, suggest that third generation OCPs put women at higher
risk of developing venous thrombosis (22, 28). Our review of the
literature to the current time leads us to conclude that no definite
recommendations can be made in favor of the safety of third gen-
eration OCPs when compared to previous generation OCPs in
women with risk factors for developing CVST. Furthermore, in
such women, non-hormonal contraceptive methods are preferred
(26, 29, 30).
We found no major studies assessing the risk of CVST with
the use of other hormonal contraceptives, such as contraceptive
rings or transdermal patches. Nonetheless, our search did reveal
a couple of case reports on CVST with the use of hormonal con-
traceptive rings (31, 32). In addition, a recent systematic review
reports a high risk of venous thrombosis (CVST not assessed)
with the use of these non-oral hormonal contraceptives (33). In
our opinion therefore, unless there is new evidence to the contrary,
these types of contraceptives should also be avoided in women with
risk factors for CVST.
Our study has limitations. Biases inherent in a case–control
study design can influence our summary estimate (34). Even
though we explored the role of potential confounders in inter-
preting a pooled estimate of the measure of association between
hormonal contraceptive use and CVST, residual confounding by
variables not studied or unknown could always exist (34). An
interaction between risk factors for CVST and hormonal con-
traceptive use was not reported in most studies and therefore
could not be explored in detail. Nonetheless, despite the limita-
tions of doing a meta-analysis of case–control studies, our study
has several strengths. First, CVST was objectively confirmed in all
studies. Second, we can conclude with confidence that the odds of
CVST is increased with the use of OCPs as compared to individu-
als not using OCPs; the studies in this area consistently show this
association. In addition, our cumulative meta-analysis demon-
strates that this association holds true and strengthens with time.
This association also has biological plausibility (2, 4).
Part of the issue in studying CVST is the rarity of this disorder
and the inability to study it in large cohort studies or random-
ized controlled trials (3). Therefore, case–control studies remain
the most feasible design in studying CVST. Future studies should
strive to improve the description of the association in question,and
future researchers in this area should be mindful of the appropriate
population to study. Variables that increase the risk of CVST, such
as pregnancy or the post-partum period, prothrombotic genetic
mutations and head trauma should be excluded in both cases
and controls. Controls should be matched to cases by age, BMI,
socioeconomic status, etc. Duration and type of hormonal con-
traceptive use and its timing in relation to CVST (for cases) or
study assessment (for controls) should be documented and then
analyzed in the results. Finally, analysis of results should include
an overall estimate of effect, but also subgroup analysis to look at
variables such as type of hormonal contraception, duration, and
timing of use.
CONCLUSION
Oral contraceptive use increases the risk of CVST in women of
reproductive age sevenfold when compared to those not using
this method of contraception. This systematic review suggests
the need for future studies to answer whether duration and
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FIGURE 4 | Assessment of publication bias in meta-analysis using a funnel plot.
type of hormonal contraceptive use modifies the risk of devel-
oping CVST. However, based on our review of the literature,
we would recommend that women with other risk factors for
thrombosis, such as smoking, immobility, history of thrombo-
sis or thrombophilia, or a past history of CVST, choose alternative
non-hormonal methods of contraception.
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